Integrated DNA Technologies is launching a new suite of next-generation sequencing products designed to address persistent bottlenecks in cancer research workflows, the genomics company announced.

By joining forces, IDT will pair its nearly 40-year legacy of quality and service, as well as its global presence, with Ansa’s breakthrough enzymatic DNA synthesis platform to accelerate the delivery of challenging motifs, higher complexity, and longer constructs.